[Expression and clinical significance of MDM2 and P16 in laryngeal squamous cell carcinoma].
To investigate the relationship between the protein expression of MDM2 and P16 in laryngeal squamous cell carcinoma (LSCC), and their relationship with clinic pathological feature. The expression of MDM2 and P16 were detected by S-P immunohistochemical method with mouse monoclonal anti MDM2 antibody and anti P16 antibody in 35 LSCC specimens, 21 specimens of precancerous larynx, 20 normal laryngeal specimens. Expression of MDM2 positive in normal laryngeal specimens, precancerous larynx and LSCC specimens were 10.0%, 38.1%, 54.3% respectively (P < 0.05), and in I - III pathological grade laryngeal carcinoma were 38.1%, 66.7%, 100.0% respectively (P < 0.05); Expression of P16 positive in normal laryngeal specimens, precancerous larynx and LSCC specimens were 85.1%, 52.4%, 34.3% respectively (P < 0.05), and in I - III pathological grade laryngeal carcinoma were 52.4%, 11.1%, 0% respectively (P < 0.05). Expression of MDM2 positive were higher with lower differentiation, so it's maybe helpful to diagnose LSCC. Expression of P16 positive were lower with lower differentiation, and there's no expression in III pathological grade LSCC, so it has positive effect on malignancy determination. Abnormal expression of MDM2 and P16 have different effects on LSCC development. Expression of MDM2 and P16 have negative correlation in LSCC.